sv8
As filed with the Securities and Exchange Commission on November 2, 2007
Registration No. 333-____________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NEUROCRINE BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
(State or Other Jurisdiction of Incorporation
or Organization)
|
|
33-0525145
(I.R.S. Employer Identification No.) |
12790 El Camino Real
San Diego, CA 92130
(Address of Principal Executive Offices)
Neurocrine Biosciences, Inc.
2003 Incentive Stock Plan, As Amended
(Full Title of the Plan)
Gary A. Lyons
President and Chief Executive Officer
Neurocrine Biosciences, Inc.
12790 El Camino Real
San Diego, CA 92130
(Name and Address of Agent for Service)
(858) 617-7600
(Telephone Number, Including Area Code, of Agent for Service)
Copies to:
|
|
|
Margaret Valeur-Jensen, J.D., Ph.D.
Executive Vice President,
General Counsel and Secretary
Neurocrine Biosciences, Inc.
12790 El Camino Real
San Diego, CA 92130
(858) 617-7600
|
|
Jason L. Kent, Esq.
Cooley Godward Kronish llp
4401 Eastgate Mall
San Diego, CA 92121
(858) 550-6000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CALCULATION OF REGISTRATION FEE |
|
|
|
|
|
|
|
|
Proposed |
|
|
|
|
|
|
|
|
Title of Each Class |
|
|
|
|
|
Maximum |
|
|
Proposed Maximum |
|
|
|
|
|
of Securities to |
|
|
Amount to be |
|
|
Offering |
|
|
Aggregate |
|
|
Amount of |
|
|
be Registered |
|
|
Registered (1) |
|
|
Price per Share (2) |
|
|
Offering Price (2) |
|
|
Registration Fee |
|
|
Common Stock (par value
$0.001 per share) |
|
|
538,449 shares (3) |
|
|
$9.79 |
|
|
$ |
5,271,416 |
|
|
|
$ |
162 |
|
|
|
|
|
|
(1) |
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement
also registers any additional shares of the Registrants common stock, par value $0.001 per share, or the Common Stock, as
may become issuable under any of the plans as a result of any stock split, stock dividend, recapitalization or similar
event. |
|
(2) |
|
This estimate is made pursuant to Rule 457(e) and Rule 457(h)(1) of
the Securities Act solely for purposes of calculating the registration
fee. The price per share and aggregate offering price are based upon
the average of the high and low prices of the Common Stock on October
26, 2007, as reported on the Nasdaq Global Select Market. |
|
(3) |
|
Represents shares reserved for issuance under the Neurocrine
Biosciences, Inc. 2003 Incentive Stock Plan, as amended, or the 2003
Plan. 500,000 of such shares were added to the 2003 Plan pursuant to
a share reserve increase approved by the Registrants stockholders in
June 2007. The remaining 38,449 shares represent awards previously
granted under the 2003 Plan that were thereafter returned to the share
reserve under the 2003 Plan upon either the settlement of such awards
without the issuance of shares or the expiration of such awards prior
to their settlement. Due to the circumstances of the original grant
of such awards, these shares were no longer eligible for resale under
Form S-8 upon their return to the share reserve of the 2003 Plan;
accordingly, such shares are being re-registered under this
Registration Statement. |
TABLE OF CONTENTS
INTRODUCTION
This Registration Statement is being filed for the purpose of increasing the number of
securities of the same class as other securities for which Registration Statements on Form S-8
relating to the same employee benefit plan are effective. We previously registered shares of our
Common Stock for issuance under the 2003 Plan under Registration Statements on Form S-8 filed with
the Securities and Exchange Commission, or SEC, on June 6, 2003 (File No. 333-105907), September 2,
2004 (File No. 333-118773), August 4, 2005 (File No. 333-127214) and July 20, 2006 (File No.
333-135909). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby
incorporates by reference the contents of the Registration Statements referenced above.
Item 6. Indemnification of Directors and Officers
Section 145 of the Delaware General Corporation Law, or the DGCL, generally allows us to
indemnify directors and officers for all expenses, judgments, fines and amounts in settlement
actually paid and reasonably incurred in connection with any proceedings so long as such party
acted in good faith and in a manner reasonably believed to be in or not opposed to our best
interests and, with respect to any criminal proceedings, if such party had no reasonable cause to
believe his or her conduct to be unlawful. Indemnification may only be made by us if the applicable
standard of conduct set forth in Section 145 has been met by the indemnified party upon a
determination made (i) by our board of directors by a majority vote of the directors who are not
parties to such proceedings, even though less than a quorum, (ii) if there are no such directors,
or if such directors so direct, by independent legal counsel in a written opinion or (iii) by the
stockholders.
Our bylaws provide for indemnification of our directors and officers to the fullest extent
permitted by law.
Section 102(b)(7) of the DGCL provides that a certificate of incorporation may include a
provision which eliminates or limits the personal liability of a director to the corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director, except for liability
(i) for any breach of the directors duty of loyalty to the company or its stockholders, (ii) for
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation
of law, (iii) under Section 174 of the DGCL, relating to prohibited dividends or distributions or
the repurchase or redemption of stock or (iv) for any transaction from which the director derives
an improper personal benefit. Our certificate of incorporation includes such a provision. As a
result of this provision, we and our stockholders may be unable to obtain monetary damages from a
director for breach of his or her duty of care.
Insofar as indemnification for liabilities under the Securities Act may be permitted to our
directors, officers or controlling persons pursuant to the foregoing provisions, we have been
informed that in the opinion of the SEC such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable.
Item 9. Undertakings
The undersigned registrant hereby undertakes:
|
(1) |
|
To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement: |
|
(i) |
|
To include any prospectus required by Section 10(a)(3) of the Securities Act; |
|
|
(ii) |
|
To reflect in the prospectus any facts or events arising after the effective
date of the Registration Statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the Registration Statement. Notwithstanding the foregoing, any
increase or decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from
the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the
changes in volume and price represent no more than a 20 percent change in the maximum
aggregate |
|
|
|
offering price set forth in the Calculation of Registration Fee table in the
effective Registration Statement; and |
|
|
(iii) |
|
To include any material information with respect to the plan of distribution
not previously disclosed in this Registration Statement or any material change to such
information in this Registration Statement; |
provided, however, that paragraphs (i) and (ii) of this section do not apply if the
Registration Statement is on Form S-8, and the information required to be included in a
post-effective amendment by those paragraphs is contained in reports filed with or furnished to the
SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities and Exchange Act of
1934, as amended, or the Exchange Act, that are incorporated by reference in the Registration
Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of this offering.
(4) That, for the purpose of determining liability of the registrant under the Securities
Act to any purchaser in the initial distribution of the securities, the undersigned registrant
undertakes that in a primary offering of securities of the undersigned registrant pursuant to this
Registration Statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser:
|
(i) |
|
Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant to Rule 424; |
|
|
(ii) |
|
Any free writing prospectus relating to the offering prepared by or
on behalf of the undersigned registrant or used or referred to by the
undersigned registrant; |
|
|
(iii) |
|
The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned registrant or
its securities provided by or on behalf of the undersigned registrant; and |
|
|
(iv) |
|
Any other communication that is an offer in the offering made by the
undersigned registrant to the purchaser. |
(5) That, for purposes of determining any liability under the Securities Act, each filing of
the registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and,
where applicable, each filing of an employee benefit plans annual report pursuant to Section 15(d)
of the Exchange Act) that is incorporated by reference in the Registration Statement shall be
deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of San Diego, State of California, on November 2, 2007.
|
|
|
|
|
|
Neurocrine Biosciences, Inc.
|
|
|
By: |
/s/ Gary A. Lyons
|
|
|
|
Gary A. Lyons |
|
|
|
President and Chief Executive Officer |
|
POWER OF ATTORNEY
Know All Persons By These Presents, that each person whose signature appears below
constitutes and appoints Gary A. Lyons and Timothy P. Coughlin, and each or
either of them, his true and lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any
and all amendments (including post-effective amendments) to this Registration Statement, and to
file the same, with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of
them, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or
any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by
virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has
been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
/s/ Gary A. Lyons
Gary A. Lyons
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
November 2, 2007 |
|
|
|
|
|
/s/ Timothy P. Coughlin
Timothy P. Coughlin
|
|
Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
November 2, 2007 |
|
|
|
|
|
/s/ Joseph A. Mollica, Ph.D.
Joseph A. Mollica, Ph.D.
|
|
Chairman of the Board of Directors
|
|
November 2, 2007 |
|
|
|
|
|
/s/ Corinne H. Lyle
Corinne H. Lyle
|
|
Director
|
|
November 2, 2007 |
|
|
|
|
|
/s/ Richard F. Pops
Richard F. Pops
|
|
Director
|
|
November 2, 2007 |
|
|
|
|
|
/s/ Stephen A. Sherwin, M.D.
Stephen A. Sherwin, M.D.
|
|
Director
|
|
November 2, 2007 |
|
|
|
|
|
/s/ Wylie W. Vale, Ph.D.
Wylie W. Vale, Ph.D.
|
|
Director
|
|
November 2, 2007 |
|
|
|
|
|
/s/ W. Thomas Mitchell
W. Thomas Mitchell
|
|
Director
|
|
November 2, 2007 |
EXHIBIT INDEX
|
|
|
Exhibits: |
|
Description |
4.1
|
|
Form of Common Stock Certificate (1) |
|
|
|
5.1
|
|
Opinion of Cooley Godward Kronish LLP |
|
|
|
10.1
|
|
Neurocrine Biosciences, Inc. 2003 Incentive Stock Plan, as amended and form
of stock option agreement and restricted stock unit agreement (2) |
|
|
|
23.1
|
|
Consent of Cooley Godward Kronish LLP (included as Exhibit 5.1 to this filing) |
|
|
|
23.2
|
|
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm |
|
|
|
24.1
|
|
Power of Attorney (included on the signature page hereto) |
|
|
|
(1) |
|
Incorporated by reference to the Companys Registration Statement on Form S-1 (Registration
No. 333-03172) |
|
(2) |
|
Incorporated by reference to the Companys Quarterly Report on Form 10-Q filed on August 2,
2007 |